McKesson Analyst Ratings
Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $535
Deutsche Bank Trims Price Target on McKesson to $623 From $631
Leerink Partners Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $665
Michael Cherny Reaffirms Buy Rating on McKesson Amid Temporary Setbacks and Long-Term Growth Prospects
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Cuts Target Price to $535
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
McKesson Is Maintained at Buy by Citigroup
McKesson Analyst Ratings
Jefferies Adjusts Price Target on McKesson to $607 From $630
Citi Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $630
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $576 to $665
Wells Fargo Gives a Hold Rating to McKesson (MCK)
Strategic Divestitures Bolster McKesson's Focus on High-Growth Oncology Market: Maintaining Buy Rating
McKesson (MCK) Gets a Buy From Barclays
McKesson Is Maintained at Outperform by Leerink Partners
McKesson Analyst Ratings
Buy Rating Maintained for McKesson Amid Long-Term Growth Prospects
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Maintains Target Price $576